- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Stool sample.
Displaying page 1 of 5.
EudraCT Number: 2019-000307-32 | Sponsor Protocol Number: Repha_1439 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:Repha GmbH | |||||||||||||
Full Title: Clinical trial for examination of efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrom (IBS-D) | |||||||||||||
Medical condition: Confirmed diagnosis of diarrhea-dominant irritable bowel syndrome (IBS-D) by a specialist physician and/or internal medicine and/or general medicine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003770-85 | Sponsor Protocol Number: DKFZ-2019-007 | Start Date*: 2020-08-20 |
Sponsor Name:German Cancer Research Center (DKFZ) | ||
Full Title: Effect of low-dose acetylsalicylic acid on early detection of advanced colorectal neoplasms | ||
Medical condition: Screening for advanced colorectal neoplasms. Male individuals aged 40 to 79 years scheduled for screening colonscopy and no use of acetylsalicylic acid (or other drugs with an effect on the blood ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004804-38 | Sponsor Protocol Number: 073-202 | Start Date*: 2011-12-13 | |||||||||||
Sponsor Name:ViroDefense Inc | |||||||||||||
Full Title: A Randomized, Blinded, Placebo-Controlled, Poliovirus Challenge Study To Evaluate The Therapeutic Efficacy, Safety, Tolerability And Pharmacokinetics Of Orally Administered V-073 In Healthy Adult V... | |||||||||||||
Medical condition: Poliomyelitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000245-12 | Sponsor Protocol Number: Repha_1436 | Start Date*: 2020-01-20 | ||||||||||||||||
Sponsor Name:Repha GmbH | ||||||||||||||||||
Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir... | ||||||||||||||||||
Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005473-10 | Sponsor Protocol Number: BEYOND | Start Date*: 2021-11-24 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: BEZLOTOXUMAB YIELDED OUTCOMES BY ADDRESSING PERSONALIZED NEEDS IN CLOSTRIDIOIDES DIFFICILE INFECTION: THE BEYOND DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Clostridioides difficile Infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001618-41 | Sponsor Protocol Number: FERARO | Start Date*: 2020-04-14 | ||||||||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | ||||||||||||||||||
Full Title: FERARO: A prospective, randomised placebo controlled feasibility trial of Faecal microbiota Transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms | ||||||||||||||||||
Medical condition: Gastrointestinal colonisation and infection with Extended Spectrum Beta-lactamase (ESBL) producing Enetrobacteriales and Carbapenemase Producing Enetrobacteriales | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001642-10 | Sponsor Protocol Number: SMT19969/C005 | Start Date*: 2019-03-13 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) LT (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019267-11 | Sponsor Protocol Number: MA-PA25CF10-01 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Axcan Pharma Inc. | |||||||||||||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, CROSS-OVER STUDY TO COMPARE THE SAFETY AND EFFICACY OF PANZYTRAT® 25 000 TO KREON® 25 000 IN THE CONTROL OF STEATORRHEA IN SUBJECTS AGED 7 YEARS AND OLDER WI... | |||||||||||||||||||||||
Medical condition: Correction of steathorrea associated with chronic exocrine pancreatic insufficiency in cystic fibrosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000180-41 | Sponsor Protocol Number: P000176 | Start Date*: 2015-04-08 |
Sponsor Name:Medical Center - University of Freiburg | ||
Full Title: Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin. | ||
Medical condition: Intestinal carriage of 3GCREB responsible for relapsing infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-001542-29 | Sponsor Protocol Number: 106260 | Start Date*: 2015-06-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family. | ||
Medical condition: Rotavirus (RV) gastroenteritis | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-005753-12 | Sponsor Protocol Number: RG_15-026 | Start Date*: 2017-11-22 |
Sponsor Name:University of Birmingham | ||
Full Title: Prospective, open-label, randomised pilot study to assess two possible routes of Faecal Microbiota Transplant (FMT) delivery in patients with ulcerative colitis. | ||
Medical condition: Ulcerative colitis for at least 3 months prior to trial entry | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003629-13 | Sponsor Protocol Number: PROFIT | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:King's College London
[...]
1. King's College London
2. King's College Hospital NHS Fundation Trust |
|||||||||||||
Full Title: A Prospective, randomised placebo controlled feasibility trial of Faecal Microbiotica Transplantation in cirrhosis | |||||||||||||
Medical condition: Cirrhosis of the liver | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001430-33 | Sponsor Protocol Number: GS-US-365-4237 | Start Date*: 2020-05-15 |
Sponsor Name:Gilead Sciences, Inc. | ||
Full Title: A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects with Moderately to Severely Active Ulcerative Colitis | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) BE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-001240-19 | Sponsor Protocol Number: CSL16001 | Start Date*: 2016-08-22 |
Sponsor Name:Synlogic | ||
Full Title: Clearance of the probiotic strain Escherichia coli Nissle 1917 in the gastrointestinal tract of healthy volunteers | ||
Medical condition: Healthy volunteers trial, intended indication: Colitis ulcerosa in phase of remission, Chronic constipation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001641-27 | Sponsor Protocol Number: SMT19969/C004 | Start Date*: 2019-07-05 | |||||||||||
Sponsor Name:Summit (Oxford) Limited | |||||||||||||
Full Title: A Phase 3, randomized, double-blind, active controlled study to compare the efficacy and safety of ridinilazole (200 mg, bid) for 10 days with vancomycin (125 mg, qid) for 10 days in the treatment ... | |||||||||||||
Medical condition: Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GR (Prematurely Ended) BG (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000775-32 | Sponsor Protocol Number: H-030-014 | Start Date*: 2013-08-13 | |||||||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur Inc | |||||||||||||||||||||||||||||||||
Full Title: Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile Infection | |||||||||||||||||||||||||||||||||
Medical condition: Prevention of primary Clostridium difficile infection | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed) DK (Completed) PL (Completed) CZ (Completed) RO (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000070-11 | Sponsor Protocol Number: MK-6072-001 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK 6072, Human Monoclonal An... | |||||||||||||
Medical condition: Prevention of recurrent Clostridium difficile infection (CDI) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Completed) PT (Completed) SE (Prematurely Ended) DE (Completed) NO (Completed) HU (Completed) PL (Completed) Outside EU/EEA GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005345-36 | Sponsor Protocol Number: D5610C00001 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Ardelyx, Inc. | |||||||||||||
Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete... | |||||||||||||
Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004977-42 | Sponsor Protocol Number: CB-01-11/28 | Start Date*: 2017-11-10 | |||||||||||
Sponsor Name:Cosmo Technologies Ltd. | |||||||||||||
Full Title: A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to pat... | |||||||||||||
Medical condition: Diarrhoea-predominant irritable bowel syndrome (IBS-D) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Temporarily Halted) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002528-17 | Sponsor Protocol Number: AC-061A301 | Start Date*: 2014-03-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
Medical condition: Clostridium difficile-associated diarrhea (CDAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
